Investor Workshop

Tuesday, October 13, 2020

Hosted by Keiretsu Forum Mid-Atlantic

Tuesday, October 13, 2020 – 3:00am to 5:00pm    
Hilton Garden Inn, 1100 Arch Street, Philadelphia, PA 19107

The 2020 Program is Being Developed – Stop Back for Updates!

Life Sciences ROI – Understanding the FDA Approval Process

Keiretsu Forum Mid-Atlantic members see more high-quality Life Sciences investments than any other K4 Region.  Each type of Life Sciences investment faces a set of FDA mandated hurdles that must be successfully addressed to allow the company to offer their product to the market.  The specific FDA approval process is different and sometimes unique based on factors that must be analyzed and factored into the equation by each of our portfolio companies.  The steps for pharma is much more difficult and time consuming than most medical devices, some get orphan drug status, some get fast tracked, and some products can get to market under GRAS – Generally Regarded as Safe.  Our team will unlock the mystery behind the required steps the FDA expects each type of Life Science company to negotiate so that you will better understand the ROI timeline.

This program is limited to Keiretsu Forum members and accredited investors registered for the Angel Capital Expo.  There are just 50 seats available for this event so register now to save a seat.  If you are an accredited investor attending the 8th Annual Angel Capital Expo and would like attend this Investor Workshop please register now:  

“The Angel Capital Expo provided INDIGO with a national forum to present the value of the Company.   As the 2017 Stephen M. Goodman Most Valued Company Award recipient, INDIGO secured over $600,000 in investments from Keiretsu Mid-Atlantic and  other angels which attended the event.  The Company surpassed its capital fundraise target because of the Angel Capital Expo!”  Fred Marroni, CEO INDIGO Biosciences